Abstract:Introduction It is widely described in the scientific literature that patients who suffer from some type of congenital syndrome such as Di George Syndrome are more likely to present some type of psychopathological alteration during their development that may require intervention and treatment by infant and juvenile mental health teams in coordination with neuropediatrics (1). On this occasion, we will present the clinical case of a patient who regularly attends psychiatry consultations for management of anxious symptoms with impulse control deficits associated with intellectual disability, diagnosed since childhood with tetralogy of Fallot and later with Di George syndrome. In this type of case, treatment is usually considered taking into account possible comorbidities at the organic level (since there may be cardiological involvement, which can be an added difficulty when taking into account the adverse effects of some psychotropic drugs) (2). Objectives This is followed by the presentation of the clinical case, which can serve to exemplify this type of case and clarify any doubts that may arise regarding treatment. Methods Presentation of the clinical case and review of updated scientific literature on the subject. Results Patient who first came to the infantile-junior consultations at the age of 8 years due to delay in the acquisition of verbal language and impulsivity. The patient had a history of pediatric follow-up since birth for different physical symptoms that finally led to the diagnosis of Di George syndrome. Given the difficulties he presented both at home and at school, different psychometric tests were performed and it was determined that it could be beneficial to initiate treatment with extended-release methylphenidate. Prior to treatment, psychomotor restlessness (without aggressiveness) and difficulty in concentration prevailed, which improved significantly after upward adjustment of the dose to a guideline corresponding to his age and weight. It was not necessary in this case to administer other treatments (the possibility of starting Aripiprazole in case of episodes of agitation was considered, but it was not necessary). The patient has continued to be monitored by cardiology to assess the possible side effects of the treatment (since it can increase heart rate and blood pressure (3), but so far no complications have been detected). Thanks to psychotherapeutic and educational intervention, language acquisition was achieved, although to date he still requires support due to the difficulties he still presents. Conclusions It is important to take into account the possible side effects of psychopharmacological treatment in patients with an associated congenital syndrome. Intensive and comprehensive follow-up by psychiatry and pediatrics (and later by their primary care physician) should be performed. Disclosure of Interest None Declared

Down syndrome regression disorder, a case series: Clinical characterization and therapeutic approaches

Down Syndrome Disintegrative Disorder: A Clinical Regression Syndrome of Increasing Importance

Case report: Down syndrome regression disorder, catatonia, and psychiatric and immunomodulatory interventions

Regression in Down Syndrome. Case Study of a Young Adult With Down Syndrome Who Was Referred to Brent Community Learning Disability Service With ‘Unexplained’ Changes in Behaviour

Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database

A Systematic Review of Unexplained Early Regression in Adolescents and Adults with Down Syndrome

De novo variants in immune regulatory genes in Down syndrome regression disorder

Down syndrome: Cognitive and behavioral functioning across the lifespan

Clinical Response to Electroconvulsive Therapy in a Young Adult With Down Syndrome Regression Disorder

Role of Immunotherapy in Down Syndrome Disintegrative Disorder (DSDD)

State‐of‐the‐art therapy for Down syndrome

Symptoms of Catatonia Observed in Down Syndrome Regressive Disorder: A Retrospective Analysis

Neuroimaging abnormalities associated with immunotherapy responsiveness in Down syndrome regression disorder

Endocrine, auxological and metabolic profile in children and adolescents with Down syndrome: from infancy to the first steps into adult life

JAK inhibition in Down Syndrome Regression Disorder

Case Report: Improvement Following Immunotherapy in an Individual With Seronegative Down Syndrome Disintegrative Disorder

Psychopharmacological management in patients with Di George syndrome

Phelan McDermid Syndrome: Multiple Sclerosis as a Rare but Treatable Cause for Regression-A Case Report

Broadening the Differential of Autoimmune Encephalitis: Diagnostic and Therapeutic Considerations in Down Syndrome Disintegrative Disorder

Clinical profile, otologic, and auditory outcomes in patients with Down syndrome

Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis